An immunotherapy clinical trial that Swim Across America provided grant funding has reached another milestone.
The Dr. Luis Diaz Lab at Memorial Sloan Kettering began receiving grants from Swim Across America in 2017. SAA grant funding allowed Dr. Diaz and his colleague, Dr. Andrea Cercek, to meet patients and conduct immunotherapy research. With SAA grant support, the lab opened a clinical trial and recruited 14 patients with advanced rectal cancer. The patients qualified through genetic testing and were treated with a single dose of immunotherapy. The patients didn’t require surgery, chemo, or radiation–which was remarkable as traditional treatments often have a negative emotional, physical, and financial effect on the quality of life for patients and their families.
Dr. Luis Diaz and Dr. Andrea Cercek
All 14 patients responded with no evidence of disease. This is believed to be the first time a clinical trial has shown a 100% response rate. Read the full story here.
Recently, the FDA Advisory Committee supported expanding the clinical trial to more patients based on the data from the trial.
The Diaz/Cercek lab has focused on rectal cancer where standard treatment options are surgery, chemotherapy, and radiation. While these treatments might save a patient, they have significant quality-of-life effects and often present the need for ongoing care.
This trial is genetically dependent and focused on advanced rectal cancer. Dr. Diaz and Dr. Cercek envision the immunotherapy being offered to patients with other cancer types who meet the genetic profile. Proceeds from the Long Island Sound and Nassau/Suffolk – Sound to Cove charity swims continue to help fund the ongoing research and clinical trial at Memorial Sloan Kettering.
Swim Across America has a proven track record of identifying and funding early-stage ideas of promise. Swim Across America grants have played a major role in clinically developing FDA-approved immunotherapy treatments ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), and atezolizumab (TECENTRIQ).
With the support of Swim Across America grant funding, researchers at Rush University Medical Center are gaining momentum in their quest to discover the early detection tools and treatment options of the future in the fight against cancer. RUSH’s experts intimately understand the physical, emotional and financial burdens of cancer on patients’ lives, and they refuse to let the disease rest as the second leading cause of death in the U.S. Since 2012, Swim Across America–Chicago has awarded More than $2M that has funded these early stage research projects.
Dr. Carl Maki
Grant Recipient: Carl Maki, PhD Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Project: Targeting proteins to improve drug responses for patients with treatment-resistant breast and lung cancers
Project Details: By studying cancer at the molecular level, Maki and his team have made significant strides in identifying promising new options for treatment-resistant breast and lung cancers.
In 2015 Maki received an SAA grant to study a family of enzymes known as prolyl peptidases (which regulate blood pressure and appetite) as a possible mechanism to help prevent or alleviate resistance to the drug tamoxifen, one of the most widely used therapies for the 80% of women with breast cancer whose tumors are considered estrogen receptor-positive. Maki and his team found that an enzyme inhibitor for prolyl peptidases, used in conjunction with tamoxifen, effectively killed breast cancer cells in rodents. Using these promising findings, Maki applied for and received a prestigious R01 research award for continued study from the National Institutes of Health and a grant from the Department of Defense to extend this research into triple-negative breast cancer.
In 2020 Maki was awarded another SAA grant to study proteins called histone demethylases in non-small cell lung cancer. Among the deadliest of all cancers, this accounts for about 4 in 5 lung cancer cases. Maki and his colleagues are studying how these proteins may allow lung cancer cells to resist the drugs currently used to treat the disease. By blocking these proteins, the team has been able to kill lung cancer cells in laboratory studies and lung tumors in mice. They identified a novel mechanism for how these inhibitors improve treatment outcomes and recently published their results.
“What starts out as an idea might result in something great,” Maki said. “SAA gives less established researchers a chance and helps all researchers fund pilot projects that ultimately can lead to bigger things.”
Dr. Animesh Barua
Grant Recipient: Animesh Barua, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College Director of the Proteomics Core and MicroRNA and Gene Expression Core
Project: Seeking an improved early detection test for ovarian cancer
Project Details: Throughout his career, Barua has relentlessly pursued the development of an effective early detection test for ovarian cancer. With an SAA grant received in 2020, he and his team are drawing upon extensive experience with immunoassays and ultrasound imaging of ovarian tumors to take the next steps forward in this important area of research. In this study, Barua’s lab is developing a fresh approach to early detection testing involving the fimbriae (fingerlike protein branches that guide an egg during ovulation) of the fallopian tubes. Emerging information shows that high-grade serous carcinoma — the most malignant and most common type of ovarian cancer — originates from the fimbriae. The aims of Barua’s study include identifying specific protein markers associated with cancer development in the fimbriae and determining the efficacy of these markers in predicting cancer growth.
Dr. Amanda Marzo
Grant Recipient: Amanda Marzo, PhD Assistant Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College
Project: Bolstering the body’s natural immune response for greater success in the battle against breast cancer
Project Details: Tumor-infiltrating CD8 T-cells are essential for tumor immunity. However, many of these cells become exhausted and are unable to protect against tumor growth. Key molecules known as checkpoint inhibitors, such as programmed death-ligand 1 (PD-L1) expressed on tumor cells and programmed cell death protein 1 (PD-1) expressed on CD8 T-cells, have been shown to be a hallmark of CD8 T-cell exhaustion. For most tumors, blocking PD-1/PD-L1 signaling does not result in tumor rejection. A main cause for the ineffectiveness of checkpoint blockade immunotherapy lies in the dysfunctional state of CD8 T-cells once they enter the tumor. CD8 T-cells are specialized in killing tumor cells but face multiple suppressive signals that dampen their ability to effectively respond. Using an SAA grant received in 2019,Marzo and her colleagues seek to improve scientists’ understanding of how other immune-modulating treatments can improve CD8 T-cell responsiveness to checkpoint inhibitors. Specifically, the researchers aim to determine if metformin, an anti-diabetic drug, could enhance tumor-infiltrating CD8 T-cell responsiveness to PD-1 blockade therapy by altering breast cancer metabolism. The team also seeks to establish if bolstering the number of infiltrating CD8 T-cells into the tumor using interleukin-15 complexes (known to cause proliferation of cells and increase their killing ability) in combination with PD-1 blockade therapy could induce regression of established breast tumors and lead to long-term tumor immunity. Marzo and her team plan to publish the results of their study and are using preliminary data generated from this research to apply for a federal R21 grant.
Dr. Alan Blank
Grant Recipients: Alan T. Blank, MD, MS Assistant Professor in the Department of Orthopedic Surgery, Section of Orthopedic Oncology at Rush Medical College
Jitesh Pratap, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Dr. Jitesh Pratap
Project: Pursuing therapeutic approaches to prevent breast cancers from
metastasizing to the bones
Project Details: In this study funded by a 2019 SAA grant, Blank and Pratap seek to fulfill a need for the development of a therapy that can prevent primary breast cancers from metastasizing to the bones and surviving there. The researchers hypothesize, based on results of previous studies, that a subgroup of patients with breast cancer that has metastasized to the bone has high levels of autophagy (a process of recycling of cellular components), Runx2 proteins and acetylated α-tubulin — worsening their chances of survival. To investigate this, the researchers are working to determine the clinicopathologic association with the autophagy pathway in tumor samples from patients with cancer that has metastasized to the bone. They are also creating patient-derived xenograft models of bone metastasis. Blank and Pratap hope the results of this study will propel the development of better combinatorial therapeutic approaches to treat bone metastasis.
Dr. Faraz Bishehsari
Grant Recipient: Faraz Bishehsari, MD, PhD Associate Professor of Medicine & the Graduate College in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Section of Gastroenterology at Rush Medical College Associate Director for Molecular & Translational Research for the Rush Center for Integrated Microbiome & Chronobiology Research
Project: Pursuing precision medicine to improve outcomes for pancreatic cancer patients
Project Details: Patients with pancreatic ductal adenocarcinoma — the most common form of pancreatic cancer — face poor survival rates, with only 6%-8% of patients surviving five years after diagnosis. This cancer does not respond well to targeted therapies. Bishehsari and his colleagues received an SAA grant in 2019 to establish a platform towards precision medicine in order to tailor therapies based on patients’ individual tumor characteristics. The researchers have developed primary cancer cells from a small tissue sample obtained during diagnostic pancreatic biopsies from pancreatic ductal adenocarcinomas. Molecular profiling of these patient-derived tumor organoids explained the variation in response to a variety of conventional and investigational therapies. They are optimizing this platform to help eventually establish individualized treatments for pancreatic cancer patients.
Dr. Jeff Borgia
Grant Recipient: Jeffrey A. Borgia, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College Director of the Rush University Cancer Center Biorepository and Rush Biomarker Development Core
Project: Identifying biomarkers for the improved evaluation and treatment of stage I non-small cell lung cancer
Project Details: Lung cancer is the leading cause of cancer-related mortality in the United States, but evidence is surfacing that widespread lung cancer screening programs may improve patient outcomes when the disease is detected early. Borgia and his team received an SAA grant in 2020 to develop a new diagnostic method to improve physicians’ ability to predict the recurrence of stage I non-small cell lung cancer, or NSCLC. This would help physicians identify patients who would benefit from adjuvant treatment options or closer surveillance. The aims of this study include identifying biomarkers for disease recurrence in stage I NSCLC patients and evaluating these biomarkers for their value in predicting recurrence.
Swim Across America has supported cancer research at Rush University Medical Center since 2012 through more than $2 million in grant funding. Together, Swim Across America and RUSH are relentlessly fighting cancer, working to save lives.
June 9, 2022—The New England Journal of Medicine published a paper on June 5 that 12 patients completed a phase 2 clinical trial for advanced rectal cancer and showed a 100% clinical complete response to dostarlimab, an immunotherapy treatment produced by GlaxoSmithKline. The clinical trial was conducted at Memorial Sloan Kettering with early-stage grant funding from Swim Across America.
Reviews of the clinical trial and quotes in the New York Times from cancer experts are hopeful:
“I believe this (a 100% response) is the first time this has happened in the history of cancer,” commented Dr. Luis Diaz, an author of the New England Journal of Medicine paper.
Dr. Luis Diaz, Memorial Sloan Kettering
“There were a lot of happy tears,” said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper.
Depending on patient size and other factors, the cost to run a clinical trial can run into millions of dollars. Early-stage sponsors such as Swim Across America are necessary to fund the costs. Swim Across America’s grant for the MSK clinical trial helped fund the science and speed of sharing of information. Other funding partners of the MSK clinical trial are the Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, and the National Cancer Institute. Swim Across America is delighted with the results and continues to provide grant support.
Swim Across America.
Swim Across America’s grant agreement with beneficiaries such as Memorial Sloan Kettering requires that 100% of an SAA grant must be spent on approved research and clinical trial programs. In 35-years, SAA has granted nearly $100M to innovative and otherwise unfunded ideas so that the time of oncologists such as Dr. Cercek and Dr. Diaz is protected to make progress and develop new treatments.
Swim Across America has a proven track record of identifying and funding early-stage ideas of promise. Swim Across America grants have played a major role in clinically developing FDA-approved immunotherapy treatments ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), and atezolizumab (TECENTRIQ).
You can volunteer or swim by visiting swimacrossamerica.org/communities
There have been many requests for sample messages to use in your fundraising efforts during the uncertainty of the current pandemic. Here are some messages created by Swim Across America staff and leading participants that you can share via email, text message, social media, the SAA fundraising app and other formats.
Message #1
Every 15 min, 50 Americans are diagnosed with cancer. Even during a pandemic, people continue to hear the terrible words ‘you have cancer’. I have joined the Swim Across America family so that I can continue to give cancer patients hope by raising funds to support cutting edge cancer research. If you are able, please support me and my swim by making a donation to my personal fundraising page. Every bit helps and will make an impact in the fight to find a cure.
Message #2
Most of us know someone who is dealing with cancer, and how devastating it can be both for the person who is ill and for the family. Cancer touches everyone, and unfortunately during these crazy times, cancer isn’t going into quarantine. That is why I’m STILL making waves to fight cancer with Swim Across America. Since we can’t be together right now, would you instead ‘buy me a drink’ or ‘take me out to dinner’ by making a donation to my Swim Across America swim. The money you give will go toward cutting edge cancer research and make an impact in the fight to find a cure.
Message #3
The past few weeks have definitely been a challenge for us all, which is why I wanted to send you a quick note to see how you were doing and to share with you on something I am looking forward to. This summer, when we are all hopefully able to come together again, I will be swimming 1 mile in open water with Swim Across America to raise funds to support cancer research. When you have a moment, check out my personal fundraising page to learn more about the event and what the funds will support. I’d love to catch up and hear what you are up to as well. Hopefully you have some fun plans to look forward to later this year too.
Message #4
I hope you are doing ok in this crazy time. I wanted to reach out to thank you again for supporting my participation in Swim Across America. It really made me smile and feel just a little bit closer during all this isolation. Did you know that you might be able to double your donation by getting a matching gift from your employer? Check with your HR department to see what forms need to be completed or search here to see if your company is eligible for matching gifts. Every bit helps, so thank you for checking with your employer for a match!
Message #5
I’ve been thinking about you and your family during this difficult time and wanted to reach out to see how you were doing. I’ve signed up to participate and fundraise to support cancer research with Swim Across America this year and they’ve been sharing these inspiring stories about dealing with uncertainty right now that I thought you might enjoy. I hope this brings a little hope to your world right now. I can’t wait until we can get together again soon.
If you have any great messages you think other SAA participants can benefit from using, you can share with us at info@swimacrossamerica.org
In 1987, an inaugural charity swim was hosted across Long Island Sound that raised $5,000 for cancer research. Since then, Swim Across America charity swims have granted nearly $100M that has funded innovative cancer research and clinical trials. Swim Across America grants have played a major role in the development of immunotherapy, detection, gene therapy and personalized medicine. The impact is that families who hear “you have cancer” are more than ever hearing “there is hope.”
In 2020, Swim Across America will be awarding a record $6 million in cancer research grants that will fund more than 50 projects and programs at the following beneficiaries: Alliance for Cancer Gene Therapy (Connecticut), Baylor Scott & White Sammons Cancer Center (Dallas), Cancer Support Team (Westchester, NY), RUSH University Medical Center (Chicago), Children’s Healthcare of Atlanta, Cold Spring Harbor Laboratory (New York), Columbia University Medical Center (New York), Dana- Farber Cancer Institute (Boston), Feinstein Institute for Medical Research (New York), Medical University of South Carolina Hollings Cancer Center (Charleston), Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore), Johns Hopkins All Children’s Hospital (Tampa), Atrium Health Levine Cancer Institute (Charlotte), MassGeneral Hospital for Children (Boston), MD Anderson Cancer Center (Houston), Memorial Sloan Kettering Cancer Center (New York), Moffitt Cancer Center (Tampa), Nantucket Cottage Hospital, Palliative and Support Care of Nantucket, Siteman Cancer Center (St. Louis), Seattle Cancer Care Alliance, UC Benioff Children’s Hospitals (San Francisco and Oakland), Children’s Hospital Colorado (Denver), University of Michigan Rogel Cancer Center (Detroit), VCU Massey Cancer Center (Richmond) and Women and Infants Hospital (Rhode Island).
In addition to these grants that are being funded by Swim Across America charity swims within their community, Swim Across America is awarding $120,000 in grants to the Conquer Cancer Foundation (American Society of Clinical Oncology—ASCO) and the American Association for Cancer Research (AACR) that will fund young investigators who have promising ideas to fight cancer.
Swim Across America partnered with the Michael Phelps Foundation for an inspiring charity swim honoring Michael’s learn-to-swim coach and cancer survivor, Cathy Bennett. The event in Mesa, Arizona raised over $55,000 that will fund a cancer research project at Johns Hopkins Kimmel Cancer Center in Baltimore.
Bennett, whom Phelps affectionately refers to as Ms. Cathy, is the Program Director of the Michael Phelps Foundation where she oversees the Foundation’s signature program – IM – which provides learn-to-swim, recreational aquatic activities, organized swim instruction, as well as health, wellness, and goal-setting programming.
Phelps, the most decorated swimmer in World Championships history and 28-time Olympic medalist, retired from competitive swimming in 2016.
Notable attendees included Dr. Bill Nelson, chief of the Kimmel Cancer Center at Johns Hopkins, three-time Olympian Allison Schmitt (2008, 2012, 2016), 2016 Olympic head coach and Arizona State University head coach Bob Bowman, and members of the ASU swim team.
In 2017, Swim Across America made a commitment to grant $1M from its Swim Across America—Atlanta charity swim to fund a pediatric acute myeloid leukemia (AML) clinical trial at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta. The total cost of the trial is $2M.
We are pleased to share that the Chick-fil-A Peach Bowl Touchdowns for Children’s (T4C) program has dedicated 2018-2019 funds raised so that the trial is fully funded. T4C allows fans to support the patients cared for at the Aflac Cancer Center, while also cheering on their favorite college football team. Fans have the chance to help pediatric cancer and blood disorders patients by pledging as little as $1 for every touchdown scored by their favorite team during the 12-game season. The program is inspired by Anna Charles Hollis. Anna was a brave patient at the Aflac Cancer Center who courageously battled AML for six months before passing away.
According to the America Society of Clinical Oncology, leukemia is the most common childhood cancer, and AML is the second most common form of leukemia in children. According to the National Pediatric Cancer Foundation, only 4% or an estimated $198M of federal government funding goes to study pediatric cancer research.
Swim Across America’s belief in the promise of the clinical trial led by Dr. Doug Graham and Dr. Deb DeRyckere, provided SAA the confidence to grant $1M to the Aflac Cancer Center. We knew additional funding from the philanthropic community would be needed so the trial could continue, and we were pleased to champion for the additional funds and are excited to partner with the Chick-fil-A Peach Bowl Touchdowns for Children’s Program.
We thank our supporters and will keep you updated on the progress of the trial.
Swim Across America is supporting the American Society of Clinical Oncology (ASCO) and ASCO’s Conquer Cancer Foundation with the creation of the Conquer Cancer Foundation of ASCO/Swim Across America Young Investigator Award (YIA). ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. As ASCO’s philanthropic affiliate, Conquer Cancer funds researchers exploring treatments for every type of cancer, for patients everywhere.
The Young Investigator Award funds the best and brightest early-career cancer researchers and represents our greatest hope for developing more promising cancer treatments. The Swim Across America YIA recipient will receive a $50,000 grant to support a year of research.
The award recipient will be named May 31 at the ASCO annual meeting in Chicago when Swim Across America will be acknowledged.
Swim Across America is more than a swim, we are a cause and we are family. Volunteers and participants more than donate, they have created a culture that SAA offers empowerment and hope.
Because of our passionate and devoted SAA supporters, in 2018, SAA granted a record $5.6 million to beneficiaries in the communities of our charity swims (Click here to see the beneficiaries). Since our founding over three decades ago, we’ve granted over $80 million dollars that has led to new cancer cures in immunotherapy, breakthroughs in new screening and detection methods, and helped to pioneer personalized medicine.
Our calendar features 20 open water charity swims. You can view the calendar and register via this link. As we look to begin our 32nd year, 2019 will be guided by this theme: Hope has no finish line. This is more than a slogan for SAA, it is to honor the life of the “amazing” Grace Bunke who we lost in 2018 from osteosarcoma at the young age of 14. Grace’s last wish was to be the #1 fundraiser for SAA and challenged our community to continue raising funds that will help doctors give hope to families in the fight against cancer. Grace’s message inspires us to think bigger about our purpose.
Please accept our heartfelt thanks for your generosity. We look forward to seeing you in 2019 as we continue to #MakeWavesToFightCancer.
Swim Across America celebrated the end of the year across the country by presenting checks to our esteemed beneficiaries. Here is a collection of smiling faces as the hard fundraising work is now seeing its impact multiplied in the fight against cancer.
Swim Across America 